Case Studies

Challenge: Our client was working with a family office which had invested in a novel IV formulation of a repurposed asset for the treatment of ischemic stroke. With a promising completed phase II...

Challenge: A clinical stage company developed two series of small molecules to treat Alzheimer Disease (AD) and other central nervous system (CNS) indications. Their lead asset aims for symptomatic...

Challenge: A biotech company developing novel gene therapy approaches for in vivo cell trans-differentiation had lead programs in IND-enabling studies for two indications. The client requested...

Challenge: A pharma company developing a first-in-class therapeutic to treat rare paediatric neurodegenerative disorders was nearing NDA approval in multiple indications and was ready to initiate...

Challenge: A midsize speciality pharmaceuticals company has retained Alacrita to conduct a series of due diligence assessments to support its business development function. The client focuses on a...

Challenge: Our client was a publicly-traded clinical-stage biopharmaceutical company using an epigenetic approach modulate gene expression in tumor and immune cells to treat cancer. Their lead...

Challenge: Our client, a global pharmaceutical company, was facing a short deadline to making an offer for a late stage gene therapy asset and was under considerable competitive deal pressure. This...

Over the past decade, our life science consulting team has provided expert guidance and hands-on support to companies, investors and academic research centers. What makes us unique is the first-hand...

Challenge: A VC investor considering funding a radiopharmaceutical company requested an analysis of the therapeutic radiopharmaceutical landscape, to help them evaluate the investment. The purpose of...

Challenge: A private equity client assessing a major investment asked Alacrita to research and assess the business development landscape for potential in-licensing or acquisition deals that could be...

Challenge: A European investor asked Alacrita to conduct a due diligence exercise on a company that had developed a novel single chain antibody platform with its lead product in ADC format ahead of a...

Challenge: A biotech client had developed a generic version of a major anti-diabetic peptide drug, and wanted a clearer understanding of the product's registrability, as well as support with defining...